Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesMobile diabetes intervention study: Testing a personalized treatment/behavioral communication intervention for blood glucose control
Contemporary Clinical Trials , 05/27/09
Quinn CC et al. - Traditional methods of disease management have not achieved adequate control for BG and other conditions important to persons with diabetes. Tools to improve communication between patients and PCPs may improve patient outcomes and be satisfactory to patients and physicians.
Related Articles
Prevention of Type 2 Diabetes: Risk Status, Clinic, and Community
Journal of General Internal Medicine, 11/09/09
Relevance Score: 96%
Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset
Diabetologia - Clinical and Experimental Diabetes and Metabolism, 10/19/09
Relevance Score: 95%
Cigarette smoking is an independent risk factor for type 2 diabetes: a four-year community-based prospective study
Clinical Endocrinology, 10/16/09
Relevance Score: 94%
Periodontal Disease – The Overlooked Diabetes Complication
Nephrology Nursing Journal, 10/07/09
Relevance Score: 94%
Testing for monogenic diabetes among children and adolescents with antibody-negative clinically defined Type 1 diabetes
Diabetic Medicine, 10/05/09
Relevance Score: 94%
Today in Major Studies...keeping you current
Receive free subspecialty "5-minute updates" via email
Evaluation of Treatment Satisfaction in Children with Allergic Disease Treated with an Antihistamine: An International, Non-Interventional, Retrospective Study
Clinical Drug Investigation, 12/11/09
Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America
Sanofi-aventis, 12/10/09
Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
Allos Therapeutics, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor